Literature DB >> 29719433

Male Oncology Research and Education program for men at high risk for prostate cancer.

J Lorentz1, S K Liu1,2, D Vesprini1,2.   

Abstract

Three groups of men are at high risk of developing prostate cancer: men with a strong family history of prostate cancer, men of West African or Caribbean ancestry, and men with a germline pathogenic variant in a prostate cancer-associated gene. Despite the fact that those men constitute a significant portion of the male population in North America, few recommendations for prostate cancer screening specific to them have been developed. For men at general population risk for prostate cancer, screening based on prostate-specific antigen (psa) has remained controversial despite the abundance of literature on the topic. As a result, recommendations made by major screening authorities are inconsistent (ranging from no psa screening to baseline psa screening at age 45), allowing physicians to pick and choose how to screen their patients. The Male Oncology Research and Education (more) program is an observational research program that serves as an academic platform for multiple research foci. For its participants, serum and dna are biobanked, medical information is collected, and contact for relevant research-related opportunities is maintained. This research program is paired with a specialized clinic called the more clinic, where men at high risk are regularly screened for prostate cancer in a standard approach that includes physical examination and serum psa measurement. In this article, we describe the goals, participant accrual to date, and projects specific to this unique program.

Entities:  

Keywords:  Prostate cancer; biobanks; cancer genetics; high-risk disease; psa; research programs; screening

Mesh:

Substances:

Year:  2018        PMID: 29719433      PMCID: PMC5927788          DOI: 10.3747/co.25.3818

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  51 in total

1.  Reevaluating PSA Testing Rates in the PLCO Trial.

Authors:  Jonathan E Shoag; Sameer Mittal; Jim C Hu
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

2.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

3.  Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.

Authors:  Tuya Pal; Susan Vadaparampil; Jongphil Kim; Yan Xu; Sue Friedman; Steven A Narod; Kelly Metcalfe
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

Review 4.  Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review.

Authors:  M A Haider; X Yao; A Loblaw; A Finelli
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-05-30       Impact factor: 4.126

Review 5.  Multigene panels in prostate cancer risk assessment: a systematic review.

Authors:  Julian Little; Brenda Wilson; Ron Carter; Kate Walker; Pasqualina Santaguida; Eva Tomiak; Joseph Beyene; Muhammad Usman Ali; Parminder Raina
Journal:  Genet Med       Date:  2015-10-01       Impact factor: 8.822

6.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Authors:  Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles
Journal:  Br J Cancer       Date:  2011-09-27       Impact factor: 7.640

Review 7.  Nutrition, dietary interventions and prostate cancer: the latest evidence.

Authors:  Pao-Hwa Lin; William Aronson; Stephen J Freedland
Journal:  BMC Med       Date:  2015-01-08       Impact factor: 8.775

8.  BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane.

Authors:  J Kotsopoulos; S Zhang; M Akbari; L Salmena; M Llacuachaqui; M Zeligs; P Sun; S A Narod
Journal:  Br J Cancer       Date:  2014-07-15       Impact factor: 7.640

9.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

10.  Rapid progression of prostate cancer in men with a BRCA2 mutation.

Authors:  S A Narod; S Neuhausen; G Vichodez; S Armel; H T Lynch; P Ghadirian; S Cummings; O Olopade; D Stoppa-Lyonnet; F Couch; T Wagner; E Warner; W D Foulkes; H Saal; J Weitzel; A Tulman; A Poll; R Nam; P Sun; Jessica Danquah; Susan Domchek; Nadine Tung; Peter Ainsworth; Douglas Horsman; Charmaine Kim-Sing; Christine Maugard; Andrea Eisen; Mary Daly; Wendy McKinnon; Marie Wood; Claudine Isaacs; Dawna Gilchrist; Beth Karlan; Raluca Nedelcu; Wendy Meschino; Judy Garber; Barbara Pasini; Siranoush Manoukian; Christina Bellati
Journal:  Br J Cancer       Date:  2008-06-24       Impact factor: 7.640

View more
  2 in total

1.  "Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.

Authors:  Michelle Skop; Justin Lorentz; Mobin Jassi; Danny Vesprini; Gillian Einstein
Journal:  Am J Mens Health       Date:  2018-02-05

Review 2.  An appraisal of genetic testing for prostate cancer susceptibility.

Authors:  Amy Finch; Roderick Clark; Danny Vesprini; Justin Lorentz; Raymond H Kim; Emily Thain; Neil Fleshner; Mohammad R Akbari; Cezary Cybulski; Steven A Narod
Journal:  NPJ Precis Oncol       Date:  2022-06-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.